drug · antibody
vedolizumab
Phase 3updated 6mo agoby $TAK TAKEDA PHARMACEUTICAL CO LTD🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 1Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for ulcerative colitis and crohn's disease and 8 investigational indications.
indications
indications
IBD (Crohn's + UC)
targets
Integrin alpha-4/beta-7
all catalysts(0)
nothing on the calendar yet
Trials studying vedolizumab
- phase4A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- —VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
- phase4A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- phase3A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- phase2Vedolizumab for the Treatment of Collagenous Gastritis
- phase3A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- phase3A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
News(10)
- Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I pushGilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolsteri…biospace · 27d ago
- Gilead’s pill posts stronger colitis remission rates than EntyvioGilead Sciences will start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival…endpoints · 28d ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
- Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successesAndy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.fiercebiotech · 2mo ago
- Schrödinger births new immunology and inflammation biotech, Tectora TherapeuticsSchrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.fiercebiotech · 2mo ago
- Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 winsSpyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.fiercebiotech · 2mo ago
- 5 NextGen winners who went public this year (and which ones are hiring)BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.biospace · 3mo ago
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaCombining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…fiercebiotech · 3mo ago
- Abivax shares surge as worries subside over immune drug’s cancer riskAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.biopharma_dive · 4mo ago
- cAMPfield lands $180M to build gut disease drugThe biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.biopharma_dive · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that